Wilmington, NC, October 05, 2012 --(PR.com
)-- Eqalix, Inc, an emerging biotechnology company in the Regenerative Medicine space, developing nanotechnologies to replicate the function of damaged, diseased or aging tissues by providing implants that are non-immunogenic and bio-compatible is scheduled to present at the 11th annual BIO Investor Forum in San Francisco at the Palace Hotel. Joseph P. Connell, CEO/President will present the Eqalix corporate scientific technology on electrospun skin, blood vessels, nerves and organs. Mr. Connell will be presenting on Tuesday October 9, 2012 at 11:45 AM in the Marina Room at the Palace Hotel.
“We are excited to finally get our story in front of the BIO community and this group of educated investors. We have been working to change the face of Wound Healing, Aesthetic Dermatology and the repair of blood vessels, nerve endings and organs themselves with our robust technology pipeline. This is the perfect venue for us,” says Connell.
About the 11th Annual BIO Investor Forum
A national investor forum to explore investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2013. Because our mission is to support industry-wide success, we strive to present a broad and unbiased view of investment opportunities. The BIO Investor Forum delivers a rich program that features corporate presentations and panel debates on the sweet spots and growth challenges facing the industry.
About Eqalix, Inc.
Eqalix, Inc. is an emerging biotechnology company operating out of Wilmington, NC, specializing in the discovery and commercialization of the use of innovative biocompatible nano-materials which are intended to restore the features and function of the damaged tissue by using the body’s own repair mechanisms that will either replace the implant with its own tissue, or transform the implant so it is perceived by the body as a natural element.
Eqalix has received exclusive commercial licensing from three prominent institutions (University of Pennsylvania, Drexel University and Children’s Hospital of Philadelphia) for several groundbreaking technologies in regenerative medicine which will revolutionize the unmet needs in multiple commercial and therapeutic applications. Using these technologies, Eqalix plans to develop and commercialize (a) plant-protein based nano-fiber scaffold for use in consumer markets and as medical devices; (b) small- diameter hybrid vessels that foster the creation of a functional endothelium after implantations and (c) 3-Dimensional tissue scaffolds with adjustable properties for organ and tissue replacement and repair.
Their technologies move the bar higher and intend to replicate the function of damaged, diseased or aging tissues by providing “implants” or scaffolds that are non-immunogenic, bio-compatible, and are intended to restore the features and function of the damaged tissue by using the body’s own repair mechanisms that will either replace the implant with its own tissue, or transform the implant so it is seen by the body as a natural extension of itself.
For Inquiries Contact:
Joseph P. Connell
President & CEO
1900 Campus Commons Drive; Suite 100
Reston, VA 20191